Page header

Recommendation of the President – Iqirvo (elafibranor)

On 2 June 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 77/2026 on the inclusion of the medicinal product Iqirvo (elafibranor) in the reimbursement program under the new drug program “Treatment of patients with primary biliary cholangitis (PBC) (ICD-10: K74.3)”

Publication in Public Information Bulletin (BIP) >>